Latest Regulatory Filings News

Fitzroy River Corporation reported steady royalty income for the June quarter and highlighted significant progress on several royalty projects, including government approvals for Buru Energy’s Rafael Gas Project and a major equity raise for Endura Mining’s Snowy River Gold development.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Helia Group’s 3Q25 APRA data reveals rising gross written premiums despite government scheme pressures, while a Board review confirms strategic focus on the Australian LMI market with significant cost cuts.

Triangle Energy (Global) Limited has amended its quarterly cash flow report to correct key figures while advancing new permits in the Philippines and progressing the transition of its Cliff Head Oil Field to a carbon capture and storage project.

Freehill Mining Limited has addressed an ASX query over the late filing of a director’s interest notice, attributing the delay to an administrative oversight and reaffirming its compliance protocols.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Anteris Technologies has enrolled the first patients in its pivotal PARADIGM Trial, testing the DurAVR Transcatheter Heart Valve against leading competitors in a global study.

Optiscan Imaging Ltd secured $17.75 million in a fully underwritten equity raise, fueling clinical studies and regulatory preparations for its innovative medical imaging devices. The company also reported progress in international trials and strengthened its cash position to nearly $20 million.

Coronado Global Resources has filed a detailed SEC Form 8-K revealing confidential discussions with noteholders and outlining its growth trajectory, liquidity management, and operational updates across its Australian and US metallurgical coal assets.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

New Frontier Minerals reports significant progress in its Harts Range and NWQ Copper projects, revealing new heavy rare earth prospects and promising copper recovery results that could accelerate production timelines.